Clinical Trial Update: Elranatamab in Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of Elranatamab for relapsed/refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: University of California, San Diego | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING